In the per-protocol population ( n = @ ) , WBRT nonsignificantly prolonged progression-free survival ( PFS ) ( median @ vs @ months , hazard ratio -LSB- HR -RSB- @ -LSB- @ % confidence interval ( CI ) @-@ @ -RSB- , p = @ ) and significantly PFS from last HDMTX ( @ vs @ months , HR @ -LSB- @ % CI @-@ @ -RSB- , p = @ ) , but without OS prolongation ( @ vs @ months , HR @ -LSB- @ % CI @-@ @ -RSB- , p = @ ) .